Table 3. Chemoradiation compliance details.
| Variable | Diclofenac arm (n = 66) | Tramadol arm (n = 62) | p value |
|---|---|---|---|
| Technique-no (%) Conventional 3DCRT Intensity modulated radiotherapy |
40 (60.6) 12 (18.2) 14 (21.2) |
48 (77.4) 1 (1.6) 13 (21) |
0.005 |
| Planned dose in Gy-no (%) 60 >60–<70 70 |
28 (42.5) 9 (13.6) 29 (43.9) |
22 (35.5) 5 (8.1) 35 (56.4) |
0.268 |
| Chemotherapy planned-no (%) 3 weekly cisplatin Weekly cisplatin Cisplatin-nimotuzumab Carboplatin Nimotuzumab Docetaxel |
- 52 (78.9) 9 (13.6) 3 (4.5) - 2 (3) |
4 (6.5) 48 (77.4) 7 (11.3) 1 (1.6) 1 (1.6) 1 (1.6) |
0.119 |
| Planned radiation dose not completed-no (%) | 4 (6) | 2 (3.2) | 1 |
| Reasons for non-completion-no (%) Default Progression Adverse event |
2 (3) 1 (1.5) 1 (1.5) |
1 (1.6) - 1 (1.6) |
- |
| Completed chemotherapy Yes No-adverse events No-patient refused |
55 (83.3) 7 (10.6) 4 (6.1) |
49 (79) 10 (16.1) 3 (4.8) |
0.69 |
| 200 mg/m2 of cisplatin received-no (%) | 49 (80.3)a | 55 (93.2)a | 0.058 |
a
n used for the percentage calculation was 61 and 59 in diclofenac and tramadol arm, respectively. This was the number of patients who received cisplatin in both arms